Analyst Ratings For Bio-Path Holdings (NASDAQ:BPTH)
Today, HC Wainwright reiterated its Buy rating on Bio-Path Holdings (NASDAQ:BPTH).
There are 3 buy ratings on the stock.
The current consensus rating on Bio-Path Holdings (NASDAQ:BPTH) is Buy (Score: 3.00) with a consensus target price of $4.00 per share, a potential 890.10% upside.
Some recent analyst ratings include
- 7/20/2017-HC Wainwright Reiterated Rating of Buy.
Recent Insider Trading Activity For Bio-Path Holdings (NASDAQ:BPTH)
Bio-Path Holdings (NASDAQ:BPTH) has insider ownership of 12.54% and institutional ownership of 19.88%.
- On 7/13/2015 Michael J Garrison, Director, bought 7,343 with an average share price of $1.22 per share and the total transaction amounting to $8,958.46. View SEC Filing
- On 7/9/2015 Michael J Garrison, Director, bought 8,724 with an average share price of $1.17 per share and the total transaction amounting to $10,207.08. View SEC Filing
- On 7/8/2015 Michael J Garrison, Director, bought 60,000 with an average share price of $1.19 per share and the total transaction amounting to $71,400.00. View SEC Filing
Recent Trading Activity for Bio-Path Holdings (NASDAQ:BPTH)
Shares of Bio-Path Holdings closed the previous trading session at 0.404 up +0.015 3.86% with 763,824 shares trading hands.